RNS Number : 0827C
Novacyt S.A.
06 February 2024
 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Update on Taiwanese divestment

 

Paris, France, and Eastleigh and Manchester, UK - 6 February 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, has received formal notification from INEX Innovate Pte Ltd of its decision to terminate discussions regarding the acquisition of Yourgene Health Taiwan Co Ltd, as originally announced by Yourgene Health plc ("Yourgene") on 13 June 2023. As a result, Yourgene's Taiwanese laboratory business will remain part of the Novacyt Group.

 

The Board does not consider the divestment material and will continue to evaluate a number of options in relation to the future of the Taiwanese laboratory business that offer the best value to all stakeholders.

 

Contacts

 

Novacyt SA

novacyt.com/investors

James McCarthy, Acting Chief Executive Officer

 Via Walbrook PR

Steve Gibson, Chief Financial Officer 

 


SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)




Deutsche Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser




Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10
 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com



Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Paul McManus /

Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7796 794 663 / +44 (0)7980 541 893

 +44 (0)7867 984 082 / +44 (0)7407 804 654





 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical

Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

·    Precision Medicine: DPYD genotyping assay

·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

 

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

·    Ranger® Technology: automated DNA sample preparation and target enrichment technology

MyGo: real-time quantitative PCR (qPCR) instruments

 

Research Use Only

Range of services for the research industry:

·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

·    Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDQKPBBOBKDQBK
Grafico Azioni Novacyt (LSE:NCYT)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Novacyt
Grafico Azioni Novacyt (LSE:NCYT)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Novacyt